+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell lysate, Primary antibody: P07233(CCNA1 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07233(CCNA1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

CCNA1 (Cyclin A1) is a member of the cyclin family, which plays a critical role in regulating cell cycle progression, particularly during the G2/M phase transition and meiotic division. Encoded by the CCNA1 gene, this protein binds to and activates cyclin-dependent kinases (CDKs), such as CDK2 and CDK1. to drive key checkpoints that ensure proper DNA replication and mitotic entry. Unlike Cyclin A2. which is ubiquitously expressed, CCNA1 is predominantly found in germ cells and certain somatic tissues, highlighting its specialized functions in cellular proliferation and differentiation.

Antibodies targeting CCNA1 are essential tools for studying its expression, localization, and interactions in both normal and pathological contexts. In research, CCNA1 antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to investigate its role in diseases, particularly cancers. Overexpression of CCNA1 has been linked to malignancies such as acute myeloid leukemia (AML), hepatocellular carcinoma, and germ cell tumors, where it may promote uncontrolled cell division and genomic instability. Additionally, these antibodies help explore CCNA1’s involvement in reproductive biology and developmental disorders.

Commercially available CCNA1 antibodies are typically raised in rabbits or mice, with monoclonal and polyclonal variants offering specificity for different applications. Validation includes testing against recombinant proteins or knockout cell lines to ensure minimal cross-reactivity. By enabling precise detection of CCNA1. these antibodies contribute to advancing understanding of cell cycle dysregulation and potential therapeutic targets in oncology and beyond.